Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

被引：0
|
作者：
Behr, J. [1 ]
Nathan, S. D. [2 ]
Harari, S. [3 ]
Wuyts, W. [4 ]
Bishop, N. Mogulkoc [5 ]
Bouros, D. E. [6 ]
Antoniou, K. [7 ]
Guiot, J. [8 ,9 ]
Kramer, M. [10 ]
Kirchgaessler, K. [11 ]
Bengus, M. [11 ]
Gilberg, F. [11 ]
Wells, A. U. [12 ]
机构：
[1] Univ Munich, Comprehens Pneumol Ctr, Internal Med 5, Munich, Germany
[2] Inova Fairfax Hosp, Falls Church, VA USA
[3] MultiMed IRCCS, Osped San Giuseppe, Serv Fisiopatol Resp, UO Pneumol & Terapia Semiintens Resp, Milan, Italy
[4] Univ Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[5] Ege Univ Hosp, Dept Pulm Med, Unit Interstitial Lung Dis, Izmir, Turkey
[6] Univ Athens, Athens, Greece
[7] Univ Crete, Dept Thorac Med, Iraklion, Crete, Greece
[8] CHU Liege, Resp Dept, Liege, Belgium
[9] CHU Liege, GIGA 13 Res Unit, Liege, Belgium
[10] Rabin Med Ctr, Pulm Inst, Petah Tiqwa, Israel
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4092
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH)
    Behr, J.
    Nathan, S. D.
    Wuyts, W. A.
    Bishop, N.
    Bouros, D. E.
    Antoniou, K.
    Guiot, J.
    Kramer, M. R.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Perjesi, A.
    Harari, S.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] Baseline Characteristics from a Pre-Specified Interim Analysis of a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
    Behr, J.
    Nathan, S. D.
    Harari, S.
    Wuyts, W.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [3] Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Results of a Responder Analysis
    Harari, S.
    Nathan, S. D.
    Behr, J.
    Wuyts, W. A.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design
    Behr, Juergen
    Nathan, Steven D.
    Harari, Sergio
    Wuyts, Wim
    Kirchgaessler, Klaus-Uwe
    Bengus, Monica
    Gilberg, Frank
    Wells, Athol U.
    [J]. RESPIRATORY MEDICINE, 2018, 138 : 13 - 20
  • [5] Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Impact on Health-Related Quality of Life
    Wuyts, W. A.
    Nathan, S. D.
    Wells, A. U.
    Harari, S. A.
    Samara, K.
    Bengus, M.
    Gilberg, F.
    Behr, J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [6] Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial
    Behr, Juergen
    Nathan, Steven D.
    Wuyts, Wim A.
    Bishop, Nesrin Mogulkoc
    Bouros, Demosthenes E.
    Antoniou, Katerina
    Guiot, Julien
    Kramer, Mordechai R.
    Kirchgaessler, Klaus-Uwe
    Bengus, Monica
    Gilberg, Frank
    Perjesi, Andras
    Harari, Sergio
    Wells, Athol U.
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (01): : 85 - 95
  • [7] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    King, Talmadge E., Jr.
    Bradford, Williamson Z.
    Castro-Bernardini, Socorro
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Gorina, Eduard
    Hopkins, Peter M.
    Kardatzke, David
    Lancaster, Lisa
    Lederer, David J.
    Nathan, Steven D.
    Pereira, Carlos A.
    Sahn, Steven A.
    Sussman, Robert
    Swigris, Jeffrey J.
    Noble, Paul W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22): : 2083 - 2092
  • [8] Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Analysis of PH Key Assessments (Right Heart Catheterization Availability and Baseline NT-proBNP)
    Behr, J.
    Nathan, S. D.
    Harari, S.
    Wuyts, W.
    Kirchgaessler, K.
    Bengus, M.
    Gilberg, F.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] The Use Of Pirfenidone In Combination With Sildenafil For Advanced Idiopathic Pulmonary Fibrosis
    Riddell, P.
    Minnis, P.
    Egan, J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [10] Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
    Costabel, Ulrich
    Albera, Carlo
    Glassberg, Marilyn K.
    Lancaster, Lisa H.
    Wuyts, Wim A.
    Petzinger, Ute
    Gilberg, Frank
    Kirchgaessler, Klaus-Uwe
    Noble, Paul W.
    [J]. RESPIRATORY RESEARCH, 2019, 20 (1):
12345